Design and rationale of a phase 3 study to evaluate the efficacy and safety of nucresiran (ALN-TTRsc04) in patients with transthyretin amyloidosis with cardiomyopathy
19 May 2025 (14:00 - 15:00)
Organised by: 
About the speaker
University College London, London (United Kingdom of Great Britain & Northern Ireland)
6 More presentations in this session
Doctor A. Georgakopoulos (Veria, GR)
Doctor K. Berge (Nordbyhagen, NO)
Doctor N. Khutsishvili (Tbilisi, GE)
Access the full session
The Event
Heart Failure 2025
19 May 2025
14:00 CET
You may be interested in
Congress Presentation
